Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1388320/000121390020033053/f10q0920_actiniumpharma.htm
SEC Filings
ATNM Annual Reports
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report May 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report February 2014
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report May 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report March 2016
10-K Annual Report March 2015
10-K Annual Report February 2014
ATNM Quarterly Reports
10-Q Quarterly Report November 2023
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report July 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2023
10-Q Quarterly Report August 2023
10-Q Quarterly Report May 2023
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report July 2021
10-Q Quarterly Report May 2021
ATNM Corporate News
Event for Officers
Vote of Security Holders December 2023
Regulated Disclosure March 2023
Financial Exhibit
Regulated Disclosure February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders December 2022
Other Events December 2022
Financial Exhibit
Regulated Disclosure October 2022
Financial Exhibit
New Agreement June 2022
New Agreement April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure September 2021
Event for Officers
Vote of Security Holders
Vote of Security Holders
December 2023
Regulated Disclosure
March 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
February 2023
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
December 2022
Other Events
December 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
October 2022
Financial Exhibit
New Agreement
New Agreement
June 2022
New Agreement
April 2022
Event for Officers
Financial Exhibit
Vote of Security Holders
Financial Exhibit
Vote of Security Holders
November 2021
Event for Officers
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
September 2021
Last10K.com | 10-Q Quarterly Report Fri Oct 23 2020
Document And Entity Information - shares | 9 Months Ended | |
|---|---|---|
Sep. 30, 2020 | Oct. 23, 2020 | |
| Document Information Line Items | ||
| Entity Registrant Name | Actinium Pharmaceuticals, Inc. | |
| Document Type | 10-Q | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | 13,586,525 | |
| Amendment Flag | false | |
| Entity Central Index Key | 0001388320 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Document Period End Date | Sep. 30, 2020 | |
| Document Fiscal Year Focus | 2020 | |
| Document Fiscal Period Focus | Q3 | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity File Number | 001-36374 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Interactive Data Current | Yes |
View differences made from one quarter to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Actinium Pharmaceuticals, Inc..
Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Other - Other Highlight
A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, which could in the future negatively affect our liquidity.
-
Financial - Shares Highlight
Specifically, the ASU eliminates the need for us to assess whether a contract on the entity's own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher shareholder's rights, and (3) whether collateral is required.
-
Other - Other Highlight
We believe our ARC approach is the most effective method to target CD45 positive cells, as the radioisotope payload linear energy transfer can readily ablate a targeted cell without requiring payload internalization like an antibody drug conjugate or without relying on biological effector function processes like a naked antibody.
-
Financial - Shares Highlight
We exercised a single ad hoc interim analysis in the second quarter of 2020 based on the data reported from SIERRA thus far that is consistent with prior findings with Iomab-B and have updated and shared the updated SIERRA trial protocol and statistical analysis plan with the FDA to reflect the single ad hoc interim analysis.
-
Financial - Expense Highlight
The decrease in expenses was primarily due to manufacturing related to the antibody component of Iomab-B, as in prior periods we have manufactured sufficient antibody supply for the SIERRA trial and other planned trials.
-
Financial - Expense
The decrease in expenses was...Read more
-
Revenue - Geography
In the European Union ("EU"),...Read more
-
Other - Other
These factors include but are...Read more
-
Financial - Expense
General and administrative expenses of...Read more
-
Financial - Expense
Net loss of $5.5 million...Read more
-
Other - Other
Results with MSKCC's 19-28z CD-19...Read more
-
Financial - Expense
Research and development expenses decreased...Read more
-
Financial - Expense
Research and development expenses decreased...Read more
-
Other - Other
Currently, the Phase 3 SIERRA...Read more
-
Other - Other
Radiation is an effective therapeutic...Read more
-
Other - Other
These non-targeted conditioning regimens are...Read more
-
Other - Other
These items are monitored and...Read more
-
Other - Other
Early adoption of the ASU...Read more
-
Other - Other
The effective life of the...Read more
-
Other - Other
Such events may result in...Read more
-
Revenue - Product
Overall, transplant procedures in the...Read more
-
Other - Other
The amendments in this ASU...Read more
-
Other - Other
This ASU is effective January...Read more
-
Other - Other
Early adoption is permitted upon...Read more
-
Other - Other
I-131-Apamistamab has clinical proof of...Read more
-
Other - Other
Furthermore, in vivo studies in...Read more
-
Other - Other
The updated guidance improves the...Read more
-
Financial - Expense
Gross proceeds from this offering...Read more
-
Financial - Expense
Gross proceeds from this offering...Read more
-
Other - Other
The universal engraftment rate and...Read more
-
Other - Other
We believe our Iomab-ACT program...Read more
-
Other - Other
Unlike chemotherapy, Iomab-ACT is targeted...Read more
-
Other - Other
Such government-imposed precautionary measures may...Read more
-
Other - Other
Further, the continuation and/or resurgence...Read more
-
Other - Other
The interim analysis is expected...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statement Of Changes In Stockholders??? Equity (Unaudited)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Accounting Policies, By Policy (Policies)
Commitments And Contingencies
Commitments And Contingencies (Details)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (Details)
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Antidilutive Securities Excluded From Computation Of Diluted Net Loss Per Share
Description Of Business And Summary Of Significant Accounting Policies (Details) - Schedule Of Cash And Cash Equivalent And Restricted Cash
Description Of Business And Summary Of Significant Accounting Policies (Tables)
Equity
Equity (Details) - Schedule Of Stock Option Activities
Equity (Details) - Schedule Of Warrant Activities
Equity (Details) - Schedule Of Warrant Activities
Equity (Details)
Equity (Tables)
Leases
Leases (Details) - Schedule Components Of Lease Expense
Leases (Details) - Schedule Of Maturities Of Lease Liabilities
Leases (Details) - Schedule Of Supplemental Cash Flow Information Related To Leases
Leases (Details) - Schedule Of Weighted Average Discount Rates
Leases (Details) - Weighted Average Remaining Lease Terms Are As Follows At September 30, 2020:
Leases (Tables)
Material Contracts, Statements, Certifications & more
Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ATNM
CIK: 1388320
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-20-033053
Submitted to the SEC: Fri Oct 23 2020 5:01:56 PM EST
Accepted by the SEC: Fri Oct 23 2020
Period: Wednesday, September 30, 2020
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/atnm/0001213900-20-033053.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...